Company / SG&A Expense
Entera Bio Ltd. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$340.0K
FY2025
5-year range
$340.0K / $7.3M
FY2021-FY2025
Trend
-92.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7M to $340,000 over the past 2 years.
Based on SEC 10-K filings.
$340,000 in FY2025 with a 3-year CAGR of -60.9%.
Improved from $7M to $340,000 over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -60.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -60.9%, indicating a declining trend.
- In FY2025, sg&a expense decreased 92.3% year-over-year.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $340.0K | -92.3% |
| FY2024 | $4.4M | -38.9% |
| FY2023 | $7.3M | +27.5% |
| FY2022 | $5.7M | +17.3% |
| FY2021 | $4.9M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026